Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity

Shanbao Cai, Haiyan Wang, Barbara Bailey, Aaron Ernstberger, Beth E. Juliar, Anthony L. Sinn, Rebecca Chan, David R. Jones, Lindsey Mayo, Arthur R. Baluyut, W. Goebel, Karen Pollok

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: Preclinical in vivo studies can help guide the selection of agents and regimens for clinical testing. However, one of the challenges in screening anticancer therapies is the assessment of off-target human toxicity. There is a need for in vivo models that can simulate efficacy and toxicities of promising therapeutic regimens. For example, hematopoietic cells of human origin are particularly sensitive to a variety of chemotherapeutic regimens, but in vivo models to assess potential toxicities have not been developed. In this study, a xenograft model containing humanized bone marrow is utilized as an in vivo assay to monitor hematotoxicity. Experimental Design: A proof-of-concept, temozolomide-based regimen was developed that inhibits tumor xenograft growth. This regimen was selected for testing because it has been previously shown to cause myelosuppression in mice and humans. The dose-intensive regimen was administered to NOD.Cg-PrkdcscidIL2rgtm1Wjl/Sz (NOD/SCID/γchainnull), reconstituted with human hematopoietic cells, and the impact of treatment on human hematopoiesis was evaluated. Results: The dose-intensive regimen resulted in significant decreases in growth of human glioblastoma xenografts. When this regimen was administered to mice containing humanized bone marrow, flow cytometric analyses indicated that the human bone marrow cells were significantly more sensitive to treatment than the murine bone marrow cells and that the regimen was highly toxic to human-derived hematopoietic cells of all lineages (progenitor, lymphoid, and myeloid). Conclusions: The humanized bone marrow xenograft model described has the potential to be used as a platform for monitoring the impact of anticancer therapies on human hematopoiesis and could lead to subsequent refinement of therapies prior to clinical evaluation.

Original languageEnglish
Pages (from-to)2195-2206
Number of pages12
JournalClinical Cancer Research
Volume17
Issue number8
DOIs
StatePublished - Apr 15 2011

Fingerprint

Bone Marrow
Heterografts
Therapeutics
temozolomide
Hematopoiesis
Bone Marrow Cells
Poisons
Cell Lineage
Glioblastoma
Growth
Research Design
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. / Cai, Shanbao; Wang, Haiyan; Bailey, Barbara; Ernstberger, Aaron; Juliar, Beth E.; Sinn, Anthony L.; Chan, Rebecca; Jones, David R.; Mayo, Lindsey; Baluyut, Arthur R.; Goebel, W.; Pollok, Karen.

In: Clinical Cancer Research, Vol. 17, No. 8, 15.04.2011, p. 2195-2206.

Research output: Contribution to journalArticle

Cai, Shanbao ; Wang, Haiyan ; Bailey, Barbara ; Ernstberger, Aaron ; Juliar, Beth E. ; Sinn, Anthony L. ; Chan, Rebecca ; Jones, David R. ; Mayo, Lindsey ; Baluyut, Arthur R. ; Goebel, W. ; Pollok, Karen. / Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 8. pp. 2195-2206.
@article{adc21035dad845cd888becabd2d7a40c,
title = "Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity",
abstract = "Purpose: Preclinical in vivo studies can help guide the selection of agents and regimens for clinical testing. However, one of the challenges in screening anticancer therapies is the assessment of off-target human toxicity. There is a need for in vivo models that can simulate efficacy and toxicities of promising therapeutic regimens. For example, hematopoietic cells of human origin are particularly sensitive to a variety of chemotherapeutic regimens, but in vivo models to assess potential toxicities have not been developed. In this study, a xenograft model containing humanized bone marrow is utilized as an in vivo assay to monitor hematotoxicity. Experimental Design: A proof-of-concept, temozolomide-based regimen was developed that inhibits tumor xenograft growth. This regimen was selected for testing because it has been previously shown to cause myelosuppression in mice and humans. The dose-intensive regimen was administered to NOD.Cg-PrkdcscidIL2rgtm1Wjl/Sz (NOD/SCID/γchainnull), reconstituted with human hematopoietic cells, and the impact of treatment on human hematopoiesis was evaluated. Results: The dose-intensive regimen resulted in significant decreases in growth of human glioblastoma xenografts. When this regimen was administered to mice containing humanized bone marrow, flow cytometric analyses indicated that the human bone marrow cells were significantly more sensitive to treatment than the murine bone marrow cells and that the regimen was highly toxic to human-derived hematopoietic cells of all lineages (progenitor, lymphoid, and myeloid). Conclusions: The humanized bone marrow xenograft model described has the potential to be used as a platform for monitoring the impact of anticancer therapies on human hematopoiesis and could lead to subsequent refinement of therapies prior to clinical evaluation.",
author = "Shanbao Cai and Haiyan Wang and Barbara Bailey and Aaron Ernstberger and Juliar, {Beth E.} and Sinn, {Anthony L.} and Rebecca Chan and Jones, {David R.} and Lindsey Mayo and Baluyut, {Arthur R.} and W. Goebel and Karen Pollok",
year = "2011",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-10-1959",
language = "English",
volume = "17",
pages = "2195--2206",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity

AU - Cai, Shanbao

AU - Wang, Haiyan

AU - Bailey, Barbara

AU - Ernstberger, Aaron

AU - Juliar, Beth E.

AU - Sinn, Anthony L.

AU - Chan, Rebecca

AU - Jones, David R.

AU - Mayo, Lindsey

AU - Baluyut, Arthur R.

AU - Goebel, W.

AU - Pollok, Karen

PY - 2011/4/15

Y1 - 2011/4/15

N2 - Purpose: Preclinical in vivo studies can help guide the selection of agents and regimens for clinical testing. However, one of the challenges in screening anticancer therapies is the assessment of off-target human toxicity. There is a need for in vivo models that can simulate efficacy and toxicities of promising therapeutic regimens. For example, hematopoietic cells of human origin are particularly sensitive to a variety of chemotherapeutic regimens, but in vivo models to assess potential toxicities have not been developed. In this study, a xenograft model containing humanized bone marrow is utilized as an in vivo assay to monitor hematotoxicity. Experimental Design: A proof-of-concept, temozolomide-based regimen was developed that inhibits tumor xenograft growth. This regimen was selected for testing because it has been previously shown to cause myelosuppression in mice and humans. The dose-intensive regimen was administered to NOD.Cg-PrkdcscidIL2rgtm1Wjl/Sz (NOD/SCID/γchainnull), reconstituted with human hematopoietic cells, and the impact of treatment on human hematopoiesis was evaluated. Results: The dose-intensive regimen resulted in significant decreases in growth of human glioblastoma xenografts. When this regimen was administered to mice containing humanized bone marrow, flow cytometric analyses indicated that the human bone marrow cells were significantly more sensitive to treatment than the murine bone marrow cells and that the regimen was highly toxic to human-derived hematopoietic cells of all lineages (progenitor, lymphoid, and myeloid). Conclusions: The humanized bone marrow xenograft model described has the potential to be used as a platform for monitoring the impact of anticancer therapies on human hematopoiesis and could lead to subsequent refinement of therapies prior to clinical evaluation.

AB - Purpose: Preclinical in vivo studies can help guide the selection of agents and regimens for clinical testing. However, one of the challenges in screening anticancer therapies is the assessment of off-target human toxicity. There is a need for in vivo models that can simulate efficacy and toxicities of promising therapeutic regimens. For example, hematopoietic cells of human origin are particularly sensitive to a variety of chemotherapeutic regimens, but in vivo models to assess potential toxicities have not been developed. In this study, a xenograft model containing humanized bone marrow is utilized as an in vivo assay to monitor hematotoxicity. Experimental Design: A proof-of-concept, temozolomide-based regimen was developed that inhibits tumor xenograft growth. This regimen was selected for testing because it has been previously shown to cause myelosuppression in mice and humans. The dose-intensive regimen was administered to NOD.Cg-PrkdcscidIL2rgtm1Wjl/Sz (NOD/SCID/γchainnull), reconstituted with human hematopoietic cells, and the impact of treatment on human hematopoiesis was evaluated. Results: The dose-intensive regimen resulted in significant decreases in growth of human glioblastoma xenografts. When this regimen was administered to mice containing humanized bone marrow, flow cytometric analyses indicated that the human bone marrow cells were significantly more sensitive to treatment than the murine bone marrow cells and that the regimen was highly toxic to human-derived hematopoietic cells of all lineages (progenitor, lymphoid, and myeloid). Conclusions: The humanized bone marrow xenograft model described has the potential to be used as a platform for monitoring the impact of anticancer therapies on human hematopoiesis and could lead to subsequent refinement of therapies prior to clinical evaluation.

UR - http://www.scopus.com/inward/record.url?scp=79954582411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954582411&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-1959

DO - 10.1158/1078-0432.CCR-10-1959

M3 - Article

C2 - 21487065

AN - SCOPUS:79954582411

VL - 17

SP - 2195

EP - 2206

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -